While not expressed in hepatocytes, FFAR2-mediated modulation of the intestinal microbiota inflammasome may have implications for NAFLD/NASH progression (Henao-Mejia et al., 2012). This evidence concerns the gene FFAR2 and metabolic dysfunction-associated steatotic liver disease.